Abstract
The Nordic countries, defined here as Norway, Sweden, Denmark, Finland and Iceland, are known for their comparable demographics and political systems. Since these countries implemented different COVID-19 intervention strategies, they provide a natural laboratory for examining how COVID-19 policies and mitigation strategies affected the propagation, evolution and spread of the SARS-CoV-2 virus. We explored how the duration, the size and number of transmission clusters, defined as country-specific monophyletic groups in a SARS-CoV-2 phylogenetic tree, differed between the Nordic countries. We found that Sweden had the largest number of COVID-19 transmission clusters followed by Denmark, Norway, Finland and Iceland. Moreover, Sweden and Denmark had the largest, and most enduring, transmission clusters followed by Norway, Finland and Iceland. In addition, there was a significant positive association between transmission cluster size and duration, suggesting that the size of transmission clusters could be reduced by rapid and effective contact tracing. Thus, these data indicate that to reduce the general burden of COVID-19 there should be a focus on limiting dense gatherings and their subsequent contacts to keep the number, size and duration of transmission clusters to a minimum. Our results further suggest that although geographical connectivity, population density and openness influence the spread and the size of SARS-CoV-2 transmission clusters, country-specific intervention strategies had the largest single impact.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
JHOP is funded by the Swedish research council FORMAS (grant no: 2015-710) and VR (grant no: 2020-02593). ECH is funded by an ARC Australian Laureate Fellowship (FL170100022). SD and LF are funded by an ARC Discovery Early Career Award awarded to SD (DE190100805). The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All SARS-CoV-2 genomes were retrieved from the GISAID platform (www.gisaid.org), for which no ethical approval was needed.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Competing interest statement All authors have read the manuscript and have no conflict of interest to declare.
Funding statement JHOP is funded by the Swedish research council FORMAS (grant no: 2015-710) and VR (grant no: 2020-02593). ECH is funded by an ARC Australian Laureate Fellowship (FL170100022). SD and LF are funded by an ARC Discovery Early Career Award awarded to SD (DE190100805). The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Data Availability
All SARS-CoV-2 genomes are available via the GISAID platform (www.gisaid.org).
